Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394972 | 0.91 | RAB9A (0.38) | ALDH1A1HPGDSTAT1LMNAOPRM1 | |
| SCHEMBL3184029 | 0.90 | SMN1; SMN2 (0.40) | ALDH1A1HPGDLMNATP53MAPT | |
| SCHEMBL3173291 | 0.85 | ALDH1A1 (0.43) | ALDH1A1HPGDSTAT1LMNATP53 | |
| SCHEMBL3179136 | 0.83 | OPRM1 (0.54) | ALDH1A1HPGDSTAT1TP53POLB | |
| SCHEMBL3168440 | 0.80 | ALDH1A1 (0.43) | ALDH1A1HPGDSTAT1LMNATP53 | |
| SCHEMBL5116460 | 0.79 | L3MBTL3 (0.48) | ALDH1A1HPGDSTAT1LMNABCHE | |
| SCHEMBL3185223 | 0.77 | DRD2 (0.35) | OPRM1OPRD1 | |
| SCHEMBL3178297 | 0.76 | PDK2 (0.41) | ALDH1A1HPGDLMNABCHEMAPT | |
| SCHEMBL3178074 | 0.75 | RAB9A (0.47) | ALDH1A1HPGDSTAT1OPRM1OPRD1 | |
| SCHEMBL3168623 | 0.72 | RAB9A (0.40) | ALDH1A1HPGDSTAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | claimed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | claimed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | claimed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | claimed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | disclosed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | disclosed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | disclosed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | disclosed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | ALDH1A1 1372/4885HPGD 926/4885STAT1 2547/4885 |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | ALDH1A1 1302/4885HPGD 860/4885STAT1 2821/4885 |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | OPRD1, OPRK1, OPRL1 | ALDH1A1 1302/4885HPGD 860/4885STAT1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.